Kirsten Rat Sarcoma Virus (KRAS) Oncoprotein as a Therapeutic Target in Multiple Myeloma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract B027: Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of RAS in multiple myeloma2026
2. 2Abstract A018: Functional chemo-genomic screening identifies novel combination therapies to treat RAS-driven multiple myeloma2026
3. 3Abstract C019: RMC-5127, a RAS(ON) G12V-selective inhibitor, drives durable tumor regressions and increases T cell infiltration in KRAS G12V-driven syngeneic models2026 · 1 citations
4. 4Abstract B024: KRAS inhibition is an effective therapy for appendiceal adenocarcinoma: Single cell profiling identifies tumor intrinsic and microenvironmental mechanisms unique to appendix cancer2026
5. 5BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma2025